|
RGPD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.95049999993391E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.15349999999059E-05 |
| Normal-vs-Stage2 |
3.212100E-04 |
| Normal-vs-Stage3 |
1.37000000000054E-06 |
| Normal-vs-Stage4 |
1.73379999999224E-05 |
| Stage1-vs-Stage2 |
3.623800E-01 |
| Stage1-vs-Stage3 |
1.192620E-01 |
| Stage1-vs-Stage4 |
8.332100E-02 |
| Stage2-vs-Stage3 |
8.422400E-01 |
| Stage2-vs-Stage4 |
5.659200E-01 |
| Stage3-vs-Stage4 |
6.171400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.36100000047712E-07 |
| Normal-vs-AfricanAmerican |
8.742600E-03 |
| Normal-vs-Asian |
7.102000E-02 |
| Caucasian-vs-AfricanAmerican |
6.661000E-01 |
| Caucasian-vs-Asian |
9.775500E-03 |
| AfricanAmerican-vs-Asian |
2.102400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.5106000000027E-05 |
| Normal-vs-Female |
5.95639999989572E-07 |
| Male-vs-Female |
8.105800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.58339999999968E-05 |
| Normal-vs-Age(41-60Yrs) |
1.93599999998018E-06 |
| Normal-vs-Age(61-80Yrs) |
2.33109999999703E-05 |
| Normal-vs-Age(81-100Yrs) |
2.972100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.073400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.830000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.800400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.012800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.291600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.924800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.542400E-02 |
| Classical-VS-Follicular |
1.855940E-02 |
| Classical-VS-Other |
6.615800E-01 |
| Classical-VS-Normal |
8.24830000000221E-05 |
| Tall-VS-Follicular |
8.121000E-01 |
| Tall-VS-Other |
5.317200E-01 |
| Tall-VS-Normal |
1.78618999999713E-05 |
| Follicular-VS-Other |
7.003400E-01 |
| Follicular-VS-Normal |
4.40049999994585E-06 |
| Other-VS-Normal |
8.060300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.22619999998186E-06 |
| Normal-vs-N1 |
4.972600E-04 |
| N0-vs-N1 |
8.337800E-01 |
|
|
